引用次数
引用: 1,258
H-指数: 18
I10-指数 : 32
出版物: 111
Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)
K. Xu , A. Lo , V. Chin , C. Gzell
Annals of Oncology 29
2018
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database
D.E. Meyers , R. Lee-Ying , M. Alghamdi , H.-W. Sim
Annals of Oncology 29
2018
Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)
H.-W. Sim , A. Stundzia , S. Pierre , U. Metser
Annals of Oncology 29
2018
Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
A.-K. Lalani , H. Li , D. Heng , L. Wood
Annals of Oncology 27
3
2016
Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer.
A. Natori , B. A. Chan , H. W. Sim , L. Ma
Current Oncology 25 ( 6) 366 -370
3
2018
Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma
Di M. Jiang , Chihiro Suzuki , Osvaldo Espin‐Garcia , Charles H. Lim
Cancer Medicine 9 ( 9) 3023 -3032
2
2020
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Andrea S. Fung , Vincent C. Tam , Daniel E. Meyers , Hao‐Wen Sim
Cancer Medicine 9 ( 13) 4640 -4647
3
2020
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
Mohammed A. Alghamdi , Carla P. Amaro , Richard Lee‐Ying , Hao‐Wen Sim
Cancer Medicine 9 ( 14) 4918 -4928
1
2020
Barriers and potential solutions to international collaboration in neuro‐oncology clinical trials: Challenges from the Australian perspective
Benjamin Y Kong , Candace Carter , Anna K Nowak , Elizabeth Hovey
Asia‐Pacific Journal of Clinical Oncology 18 ( 3) 259 -266
5
2022
Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma
Danielle Klingberg , Susie Bae , Deborah Di‐Xin Zhou , Hao‐Wen Sim
Asia‐Pacific Journal of Clinical Oncology
1
2023
Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience
Jennifer Lim , Syafiq Akbar Ali , Amy Prawira , Hao‐Wen Sim
Internal Medicine Journal 53 ( 2) 242 -249
2
2023
Oncological outcomes post transoral robotic surgery (TORS) for HPV-associated oropharyngeal squamous cell carcinoma, a single-centre retrospective Australian study
Belen Kornfeld , Ahmed Taha , Lee Kyang , Hao-wen Sim
Journal of Robotic Surgery 18 ( 1) 226 -226
2024
Severe Intracranial Hypertension Associated with Tetracycline Use in Non-Small Cell Lung Cancer
Graham Lakkis , Hao-Wen Sim , Linda Mileshkin , Dean Cugley
American Journal of Cancer Case Reports 3 ( 3) 148 -153
2015
A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY
Erik Sulman , Matthew Foote , Michael Buckland , Michael Back
Neuro-oncology 21 18 -18
2019
Altered presentation of oropharyngeal cancer, a 6-year review.
Brett C Leavers , Rachael A McCloy , Venessa T Chin , Venessa T Chin
Anz Journal of Surgery
1
2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Eric Van Cutsem , Richard Greil , Teresa Macarulla , Johanna Bendell
Journal of Clinical Oncology 39 ( 10) 1108 -1118
42
2021
A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Erik P Sulman , Matthew C Foote , Matthew C Foote , Michael E Buckland
Neuro-oncology
2021
Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.
Steven Yip , Connor Wells , Raphael Brandao Moreira , Alex Wong
Journal of Clinical Oncology 35 492 -492
4
2017
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).
Naveen S. Basappa , Aly-Khan A. Lalani , Haocheng Li , Austin Kalirai
Journal of Clinical Oncology 35 468 -468
5
2017
Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Neeraj Agarwal , Sun Young Rha , Ravindran Kanesvaran , Toni K. Choueiri
Journal of Clinical Oncology 35 498 -498
3
2017